Amy C. Peterson Insider Trading $BGNE BeiGene, Ltd.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Amy C. Peterson.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Amy C. Peterson. Amy C. Peterson is EVP, Chief Development Officer in CytomX Therapeutics, Inc. ($CTMX) and CMO, Immuno-oncology in BeiGene, Ltd. ($BGNE).
Amy C. Peterson in BeiGene, Ltd.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Amy C. Peterson: CMO, Immuno-oncology
Holdings: 9,859 shares
Current Value: $354,135
Latest Transaction: Dec 19 2018
$BGNE Market Capitalization: $1.14B
$BGNE Previous Close: $35.92
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Amy C. Peterson in BeiGene, Ltd.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | M | 2.24 | 131,833 | 295,306 | 820,000 | |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | M | 2.24 | 128,167 | 287,094 | 951,833 | |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 135.54 | 611 | 82,816 | 0 | 611 to 0 (-100.00 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 134.81 | 3,600 | 485,316 | 611 | 4.2 K to 611 (-85.49 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 133.88 | 2,402 | 321,585 | 4,211 | 6.6 K to 4.2 K (-36.32 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 132.70 | 1,897 | 251,735 | 6,613 | 8.5 K to 6.6 K (-22.29 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 131.74 | 1,631 | 214,860 | 8,510 | 10.1 K to 8.5 K (-16.08 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Buy | M | 29.10 | 10,141 | 295,103 | 10,141 | 0 to 10.1 K |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 136.93 | 480 | 65,726 | 0 | 480 to 0 (-100.00 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 136.25 | 2,296 | 312,818 | 480 | 2.8 K to 480 (-82.71 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 135.05 | 778 | 105,065 | 2,776 | 3.6 K to 2.8 K (-21.89 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 133.81 | 1,005 | 134,479 | 3,554 | 4.6 K to 3.6 K (-22.04 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 132.91 | 1,700 | 225,953 | 4,559 | 6.3 K to 4.6 K (-27.16 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 131.80 | 2,700 | 355,852 | 6,259 | 9 K to 6.3 K (-30.14 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 130.37 | 900 | 117,331 | 8,959 | 9.9 K to 9 K (-9.13 %) |
| Dec 19 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Buy | M | 29.10 | 9,859 | 286,897 | 9,859 | 0 to 9.9 K |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | M | 2.24 | 156,871 | 351,391 | 1,080,000 | |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | M | 2.24 | 171,886 | 385,025 | 1,236,871 | |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | M | 2.24 | 191,243 | 428,384 | 1,408,757 | |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 121.56 | 100 | 12,156 | 0 | 100 to 0 (-100.00 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 117.61 | 109 | 12,820 | 100 | 209 to 100 (-52.15 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 116.56 | 500 | 58,281 | 209 | 709 to 209 (-70.52 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 114.96 | 700 | 80,472 | 709 | 1.4 K to 709 (-49.68 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 113.92 | 1,173 | 133,630 | 1,409 | 2.6 K to 1.4 K (-45.43 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 113.03 | 2,527 | 285,632 | 2,582 | 5.1 K to 2.6 K (-49.46 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 112.18 | 4,000 | 448,720 | 5,109 | 9.1 K to 5.1 K (-43.91 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 111.10 | 2,958 | 328,638 | 9,109 | 12.1 K to 9.1 K (-24.51 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Buy | M | 29.10 | 12,067 | 351,150 | 12,067 | 0 to 12.1 K |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 125.97 | 100 | 12,597 | 0 | 100 to 0 (-100.00 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 123.75 | 322 | 39,847 | 100 | 422 to 100 (-76.30 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 122.55 | 2,046 | 250,733 | 422 | 2.5 K to 422 (-82.90 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 121.71 | 2,898 | 352,704 | 2,468 | 5.4 K to 2.5 K (-54.01 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 120.63 | 2,100 | 253,325 | 5,366 | 7.5 K to 5.4 K (-28.13 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 119.27 | 1,725 | 205,740 | 7,466 | 9.2 K to 7.5 K (-18.77 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 118.64 | 4,031 | 478,218 | 9,191 | 13.2 K to 9.2 K (-30.49 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Buy | M | 29.10 | 13,222 | 384,760 | 13,222 | 0 to 13.2 K |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 127.61 | 200 | 25,522 | 0 | 200 to 0 (-100.00 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 126.72 | 7,673 | 972,320 | 200 | 7.9 K to 200 (-97.46 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 126.08 | 3,949 | 497,879 | 7,873 | 11.8 K to 7.9 K (-33.40 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 124.48 | 2,423 | 301,605 | 11,822 | 14.2 K to 11.8 K (-17.01 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 122.86 | 466 | 57,251 | 14,245 | 14.7 K to 14.2 K (-3.17 %) |
| Nov 13 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Buy | M | 29.10 | 14,711 | 428,090 | 14,711 | 0 to 14.7 K |
| Aug 24 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 170.46 | 961 | 163,815 | 0 | 961 to 0 (-100.00 %) |
| Aug 24 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 169.75 | 1,400 | 237,656 | 961 | 2.4 K to 961 (-59.30 %) |
| Aug 24 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 168.94 | 2,300 | 388,565 | 2,361 | 4.7 K to 2.4 K (-49.35 %) |
| Aug 24 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 167.54 | 1,108 | 185,630 | 4,661 | 5.8 K to 4.7 K (-19.21 %) |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | A | 12.34 | 310,180 | 3,827,621 | 310,180 | |
| Jun 28 2018 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Grant | A | 0.00 | 44,564 | 0 | 269,566 | 225 K to 269.6 K (+19.81 %) |
| Nov 15 2017 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 83.31 | 1,201 | 100,054 | 0 | 1.2 K to 0 (-100.00 %) |
| Nov 15 2017 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Sell | S | 82.79 | 2,400 | 198,693 | 1,201 | 3.6 K to 1.2 K (-66.65 %) |
| Aug 24 2017 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Payment of Exercise | F | 5.39 | 28,185 | 151,830 | 271,815 | 300 K to 271.8 K (-9.39 %) |
| Jun 29 2017 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | A | 3.49 | 1,016,178 | 3,546,461 | 1,016,178 | |
| Aug 24 2016 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Option Exercise | A | 2.24 | 1,600,000 | 3,584,000 | 1,600,000 | |
| Aug 24 2016 | BGNE | BeiGene, Ltd. | Peterson Amy C. | CMO, Immuno-oncolog ... | Grant | A | 0.00 | 300,000 | 0 | 300,000 | 0 to 300 K |
Page: 1